Jess321
2021-11-11
Like pls
FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":870523956,"tweetId":"870523956","gmtCreate":1636636151859,"gmtModify":1636636152226,"author":{"id":4087638013719750,"idStr":"4087638013719750","authorId":4087638013719750,"authorIdStr":"4087638013719750","name":"Jess321","avatar":"https://static.tigerbbs.com/dc86625c205fcfa9eb51b6291af7f62d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":31,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/870523956","repostId":1137836759,"repostType":4,"repost":{"id":"1137836759","pubTimestamp":1636634651,"share":"https://www.laohu8.com/m/news/1137836759?lang=&edition=full","pubTime":"2021-11-11 20:44","market":"us","language":"en","title":"FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1137836759","media":"Benzinga","summary":"The FDA has signed off Sight Sciences Inc's clinical study to assess investigational higher volume O","content":"<ul>\n <li>The FDA has signed off <b>Sight Sciences Inc's</b> clinical study to assess investigational higher volume OMNI device to perform canal viscodilation alone to lower intraocular pressure (IOP) in adults with primary open-angle glaucoma (POAG).</li>\n <li>The PRECISION trial is designed as a three-armed randomized controlled trial with patients receiving micro-invasive glaucoma surgery (MIGS) interventions in conjunction with cataract surgery (n=459).</li>\n <li>The devices that will be evaluated in the study are the higher volume OMNI (Sight Sciences) and <b>Glaukos Corp's</b> (NYSE: GKOS) iStent Inject Canal Implant.</li>\n <li>The PRECISION study will evaluate the safety and efficacy of higher volume OMNI for use in canaloplasty without sequential trabeculectomy.</li>\n <li>The higher volume OMNI dispenses a higher volume of viscoelastic fluid (21 microliters) higher than the currently marketed OMNI Surgical System (11 microliters).</li>\n <li>For Q3, Sight Sciencesgenerated revenue of $13.1 million, +51% Y/Y, and gross margin expanded to 84% from 70% a year ago.</li>\n <li>The growth was primarily driven by an increase in the number of facilities ordering OMNI and utilization per ordering facility during Q3.</li>\n <li>The Company posted a smaller net loss of $(17.2) million compared to $8.1 million a year ago.</li>\n <li>Cash and cash equivalents totaled $271.5 million, and total debt was $32.5 million.</li>\n <li><b>Price Action:</b> SGHT shares are up 1.16% at $24.23 during the premarket session on the last check Thursday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 20:44 GMT+8 <a href=https://www.benzinga.com/news/21/11/24037340/fda-clears-sight-sciences-trial-of-canaloplasty-combined-with-cataract-surgery-to-lower-ocular-press><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has signed off Sight Sciences Inc's clinical study to assess investigational higher volume OMNI device to perform canal viscodilation alone to lower intraocular pressure (IOP) in adults with ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/24037340/fda-clears-sight-sciences-trial-of-canaloplasty-combined-with-cataract-surgery-to-lower-ocular-press\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SGHT":"Sight Sciences, Inc."},"source_url":"https://www.benzinga.com/news/21/11/24037340/fda-clears-sight-sciences-trial-of-canaloplasty-combined-with-cataract-surgery-to-lower-ocular-press","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137836759","content_text":"The FDA has signed off Sight Sciences Inc's clinical study to assess investigational higher volume OMNI device to perform canal viscodilation alone to lower intraocular pressure (IOP) in adults with primary open-angle glaucoma (POAG).\nThe PRECISION trial is designed as a three-armed randomized controlled trial with patients receiving micro-invasive glaucoma surgery (MIGS) interventions in conjunction with cataract surgery (n=459).\nThe devices that will be evaluated in the study are the higher volume OMNI (Sight Sciences) and Glaukos Corp's (NYSE: GKOS) iStent Inject Canal Implant.\nThe PRECISION study will evaluate the safety and efficacy of higher volume OMNI for use in canaloplasty without sequential trabeculectomy.\nThe higher volume OMNI dispenses a higher volume of viscoelastic fluid (21 microliters) higher than the currently marketed OMNI Surgical System (11 microliters).\nFor Q3, Sight Sciencesgenerated revenue of $13.1 million, +51% Y/Y, and gross margin expanded to 84% from 70% a year ago.\nThe growth was primarily driven by an increase in the number of facilities ordering OMNI and utilization per ordering facility during Q3.\nThe Company posted a smaller net loss of $(17.2) million compared to $8.1 million a year ago.\nCash and cash equivalents totaled $271.5 million, and total debt was $32.5 million.\nPrice Action: SGHT shares are up 1.16% at $24.23 during the premarket session on the last check Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":27,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/870523956"}
精彩评论